BCAT-IN-4 - An Overview
The greater difference from placebo viewed to the IFN-high sufferers supports the speculation the peripheral blood IFN test standing demonstrates systemic kind I IFN activity. In distinction, for IFN-low sufferers there was a more compact distinction in response rates amongst the placebo and the 200 mg or 1200 mg regular sifalimumab teams.Meanwhi